GENINUS Inc. Stock: price and insider trades · South Korea

GENINUS Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). Over the twelve months to 1 November 2026, 13 filings were filed, from 10 insiders.

The record shows 10 purchases on the open market worth €640k, made by 9 insiders, against 2 sales worth €23k by 2 insiders. The amount is not disclosed for 5 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €229k from Kim Jaewon, disclosed on 29 May 2026, or 0.47% of market capitalisation. Among those who bought: 2 board members and 1 major shareholder.

In all, 5 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (4 August 2026) now reads 97 days. Typically, a trade is published a median of 7 days after it takes place. This delay matters because a trade only becomes useful information once it is public.

Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 13 filings, this issuer sits above that mark. Our records for GENINUS Inc. go back to 2021, with 31 purchases and 2 sales on the open market in total.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.